EUVIMEDObjevte EUVIMED
Multizentrische Studie

Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma

Alice Yu iD, Patrick J Hensley, Heather L Huelster, Austin Martin iD, Aaron Potrezke, Jonathan Pham, Jay D Raman, Maximilian Pallauf iD, Nirmish Singla, Andrew Katims, Jonathan Coleman, Vitaly Margulis iD and 2 more

BJU International · 2025

DOI: 10.1111/bju.16655 ↗

At a glance

Multizentrische Studie in BJU International, 2025. Written by Alice Yu and 13 co-authors. Institution: Moffitt Cancer Center, Tampa, Florida, USA. Major MEDLINE topics: Neoadjuvant Therapy, Carcinoma, Transitional Cell, Ureteral Neoplasms, Kidney Neoplasms. Cited 5 times so far (Crossref); 11 references. Funded by: the Paracelsus Medical University Research and Innovation Fund, Eleanor and Scott Petty Fund for Research on UTUC, Monteleone Family Foundation for Research in Kidney and Bladder Cancer.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objectives

To evaluate the benefit of neoadjuvant chemotherapy (NAC) for patients with high‐risk upper tract urothelial carcinoma (UTUC) using a large, well‐curated multi‐institutional database. Patients and Methods This study was a multi‐institutional retrospective analysis conducted by the UTUC Collaborative Network (UCAN), combining data from 2276 patients with UTUC who underwent radical nephroureterectomy at seven high‐volume tertiary care centres in the United States. The UCAN data were analysed to evaluate the impact of response to NAC on survival outcomes in patients with UTUC.

Results

A total of 378 patients in the UCAN database underwent NAC. On final surgical pathology, 101 patients (26.8%) had ≤ypT1N0 disease and were defined as NAC treatment responders. Patients who responded to NAC had significantly longer overall survival (OS) and progression‐free survival (PFS) compared to non‐responders. At 5 years post‐surgery, 81.5% of responders were alive compared to 59.8% of non‐responders. The median OS and PFS times among non‐responders were 7.0 years (95% confidence interval [CI] 5.6–9.7) and 6.0 years (95% CI 4.6–9.3) respectively, while the median OS and PFS were not reached among responders. Limitations of this study include its retrospective design, heterogeneity in chemotherapy regimens, and the absence of clearly defined patient selection criteria for treatment.

Conclusion

These data suggest that NAC can play a pivotal role in the treatment of well‐selected UTUC patients who respond positively. Non‐responders had clearly inferior outcomes. More work is needed to find predictors of response which can improve patient selection.

Subjects

MeSH terms (MEDLINE)

Neoadjuvant TherapyCarcinoma, Transitional CellUreteral NeoplasmsKidney NeoplasmsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedChemotherapy, AdjuvantNephroureterectomyTreatment Outcome

Author keywords

carcinomachemotherapyneoadjuvantnephroureterectomyurothelial

Authors and institutions

  • Moffitt Cancer Center, Tampa, Florida, USA.
  • University of Kentucky, Lexington, Kentucky, USA.
  • Mayo Clinic, Rochester, Minnesota, USA.
  • Penn State Health, Hershey, Pennsylvania, USA.
  • Johns Hopkins University, Baltimore, Maryland, USA.
  • University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.

ORCID profiles: Alice Yu, Austin Martin, Maximilian Pallauf, Vitaly Margulis, Surena F Matin

Funding

  • the Paracelsus Medical University Research and Innovation Fund
  • Eleanor and Scott Petty Fund for Research on UTUC
  • Monteleone Family Foundation for Research in Kidney and Bladder Cancer

Cite

APA

Yu, A., Hensley, P. J., Huelster, H. L., Martin, A., Potrezke, A., Pham, J., Raman, J. D., Pallauf, M., Singla, N., Katims, A., Coleman, J., Margulis, V., Matin, S. F., & Spiess, P. E. (2025). Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma. BJU International. https://doi.org/10.1111/bju.16655

Vancouver

Yu A, Hensley PJ, Huelster HL, Martin A, Potrezke A, Pham J, et al. Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma. BJU International. 2025. doi:10.1111/bju.16655

BibTeX
@article{Yu2025,
  author = {Yu, Alice and Hensley, Patrick J and Huelster, Heather L and Martin, Austin and Potrezke, Aaron and Pham, Jonathan and Raman, Jay D and Pallauf, Maximilian and Singla, Nirmish and Katims, Andrew and Coleman, Jonathan and Margulis, Vitaly and Matin, Surena F and Spiess, Philippe E},
  title = {Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16655}
}
Start for free →